Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...5152535455565758596061...266267»
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion, Checkpoint inhibition:  Neoadjuvant and Adjuvant Checkpoint Blockade (clinicaltrials.gov) -  Feb 8, 2023   
    P2,  N=53, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Dec 2022 Active, not recruiting --> Completed
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) -  Feb 6, 2023   
    P1/2,  N=3, Terminated, 
    Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Mar 2023 N=45 --> 3 | Trial completion date: Nov 2023 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Feb 2023; Lack of accrual
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Nivolumab plus Ipilimumab Induced IPEX-like Polyendocrinopathy in Sarcomaoid Renal Cell Carcinoma () -  Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1790;    
    Despite the development of an exceptionally uncommon spectrum irAEs, the patient achieved clinical remission. The following case highlights 1) the management of immunotherapy related polyendocrinopathy, 2) patients with more irAEs have improved response to therapy, 3) the critical role of FOXP3+Tregs in mediating the balance between cancer and autoimmunity.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Tecentriq (atezolizumab) / Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Adverse events, Checkpoint inhibition:  Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database. (Pubmed Central) -  Feb 4, 2023   
    The following case highlights 1) the management of immunotherapy related polyendocrinopathy, 2) patients with more irAEs have improved response to therapy, 3) the critical role of FOXP3+Tregs in mediating the balance between cancer and autoimmunity. ICIs had possible strong signals associated with hepatic failure, and most cases of hepatic failure occurred within the first 3 months and had poor outcomes, which should attract clinical attention.
  • ||||||||||  MODULE 2: Evidence-Based Selection of First-Line Therapy for Metastatic RCC (San Francisco Marriott Marquis, Yerba Buena Ballroom ) -  Feb 2, 2023 - Abstract #ASCOGU2023ASCO_GU_915;    
    CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and supported through educational grants provided by Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck. Key clinical and biologic factors guiding the selection of first-line therapy for patients with newly diagnosed metastatic RCC Published efficacy and safety findings with nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib for treatment-na
  • ||||||||||  MODULE 1: Available Data with and Ongoing Investigation of Immune Checkpoint Inhibitors in Nonmetastatic Renal Cell Carcinoma (RCC) (San Francisco Marriott Marquis, Yerba Buena Ballroom ) -  Feb 2, 2023 - Abstract #ASCOGU2023ASCO_GU_914;    
    CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and supported through educational grants provided by Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck. Historical data with tyrosine kinase inhibitors (TKIs) as adjuvant therapy for high-risk RCC Biologic rationale for the assessment of immune checkpoint inhibitors as adjuvant therapy for RCC Design, eligibility criteria and primary and secondary endpoints of the Phase III KEYNOTE-564 trial of pembrolizumab versus placebo as adjuvant treatment for patients with clear cell RCC at increased risk of recurrence following nephrectomy Published efficacy and safety findings from KEYNOTE-564 showing a disease-free survival advantage with adjuvant pembrolizumab FDA approval of and identification of patients for treatment with adjuvant pembrolizumab Primary data from the Phase III IMmotion010 and CheckMate 914 studies demonstrating a lack of benefit with atezolizumab monotherapy and nivolumab/ipilimumab, respectively, versus placebo as adjuvant therapy for localized RCC; implications for clinical practice Ongoing Phase III studies (eg, PROSPER RCC, RAMPART trials) evaluating immune checkpoint inhibition as neoadjuvant and/or adjuvant therapy for patients with high-risk RCC
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Metastases:  Utility of prognostic prediction by early assessment of response to combined treatment with nivolumab plus ipilimumab in patients with treatment-naïve metastatic renal cell carcinoma. (Pubmed Central) -  Feb 2, 2023   
    Historical data with tyrosine kinase inhibitors (TKIs) as adjuvant therapy for high-risk RCC Biologic rationale for the assessment of immune checkpoint inhibitors as adjuvant therapy for RCC Design, eligibility criteria and primary and secondary endpoints of the Phase III KEYNOTE-564 trial of pembrolizumab versus placebo as adjuvant treatment for patients with clear cell RCC at increased risk of recurrence following nephrectomy Published efficacy and safety findings from KEYNOTE-564 showing a disease-free survival advantage with adjuvant pembrolizumab FDA approval of and identification of patients for treatment with adjuvant pembrolizumab Primary data from the Phase III IMmotion010 and CheckMate 914 studies demonstrating a lack of benefit with atezolizumab monotherapy and nivolumab/ipilimumab, respectively, versus placebo as adjuvant therapy for localized RCC; implications for clinical practice Ongoing Phase III studies (eg, PROSPER RCC, RAMPART trials) evaluating immune checkpoint inhibition as neoadjuvant and/or adjuvant therapy for patients with high-risk RCC No abstract available
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal:  Research landscape and trends of melanoma immunotherapy: A bibliometric analysis. (Pubmed Central) -  Jan 27, 2023   
    "Improved survival with ipilimumab in patients with metastatic melanoma" by Hodi et al...The researchers can benefit in selecting journals and in finding potential collaborators. This study can help researchers gain a comprehensive impression of the research landscape, historical development, and current hotspots in melanoma immunotherapy and can provide inspiration for future research.